Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(4832)
•••

Post by nozzpackon Dec 01, 2021 8:11am

279 Views

Post# 34183963

Isotrentoin Market in US had 17.8 % Growth 2021

According to Symphony Health, the U.S. isotretinoin prescription market increased by 17.8% in the nine-month period ended September 30, 2021 compared to the nine-month period ended September 30, 2020.
I assume that this prescription growth was driven by generics including generic Absorica.

Cipher generates $10 million US per year in revenues from Epuris which is the Canadian generic.

Am I not correct that all Absorica formulations sold by Teva in the US reverts to Cipher in November 2022 ?

<< Previous

Bullboard Posts

Next >>

A new NASDAQ listing for a key player in the global critical minerals space